Cargando…

Stereotactic body radiotherapy in combination with non-frontline PD-1 inhibitors and targeted agents in metastatic renal cell carcinoma

BACKGROUND: Radiotherapy may work synergistically with immunotherapy and targeted agents. We aimed to assess the safety and outcomes of stereotactic body radiotherapy (SBRT) plus non-first-line programmed death-1 (PD-1) inhibitors and targeted agents (TA) in metastatic renal cell carcinoma (mRCC). M...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Yang, Zhang, Zhiling, Liu, Ruiqi, Wei, Wensu, Zhang, Zitong, Mai, Lixin, Guo, Shengjie, Han, Hui, Zhou, Fangjian, He, Liru, Dong, Pei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8561986/ https://www.ncbi.nlm.nih.gov/pubmed/34727963 http://dx.doi.org/10.1186/s13014-021-01937-9

Ejemplares similares

Metastasis-directed stereotactic body radiotherapy for oligometastatic renal cell carcinoma: extent of tumor burden eradicated by radiotherapy
por: Liu, Yang, et al.
Publicado: (2021)

Survival After Combining Stereotactic Body Radiation Therapy and Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma
por: Liu, Yang, et al.
Publicado: (2021)

Survival Outcomes After Adding Stereotactic Body Radiotherapy to Metastatic Renal Cell Carcinoma Patients Treated With Tyrosine Kinase Inhibitors
por: He, Liru, et al.
Publicado: (2020)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Mai, Lixin, et al.
Publicado: (2020)

Cytoreductive radiotherapy combined with abiraterone in metastatic castration-resistance prostate cancer: a single center experience
por: Liu, Yang, et al.
Publicado: (2021)

Survival Outcomes and Prognostic Analysis Following Greater Cytoreductive Radiotherapy in Patients With Metastatic Prostate Cancer
por: Zhang, Zitong, et al.
Publicado: (2020)

Stereotactic body radiotherapy-induced abscopal effect twice after pembrolizumab failure in hereditary leiomyomatosis and renal cell carcinoma: a case report with genetic and immunologic analysis
por: Zhang, Xinyue, et al.
Publicado: (2021)

Successful management of prostate cancer with bulky pelvic lymph node metastases after rapid development of castration-resistant prostate cancer: a case report with review of the literature
por: Mai, Lixin, et al.
Publicado: (2020)

Special issue “The advance of solid tumor research in China”: 68Ga‐PSMA‐11 PET/CT for evaluating primary and metastatic lesions in different histological subtypes of renal cell carcinoma
por: Li, Yilin, et al.
Publicado: (2022)

Locoregional recurrence after nephrectomy for localized renal cell carcinoma: Feasibility and outcomes of different treatment modalities
por: Liu, Yang, et al.
Publicado: (2022)

Stereotactic body radiotherapy extends the clinical benefit of PD-1 inhibitors in refractory recurrent/metastatic nasopharyngeal carcinoma
por: Lin, Jing, et al.
Publicado: (2022)

Long noncoding RNAs to predict postoperative recurrence in bladder cancer and to develop a new molecular classification system
por: Li, Zhiyong, et al.
Publicado: (2021)

Stereotactic Body Radiotherapy for Metastatic and Recurrent Ewing Sarcoma and Osteosarcoma
por: Brown, Lindsay C., et al.
Publicado: (2014)

Immune checkpoint inhibitors further aggravate proteinuria in patients with metastatic renal cell carcinoma after long-term targeted therapy
por: Ning, Kang, et al.
Publicado: (2022)

Conventional Radiotherapy and Stereotactic Radiosurgery in the Management of Metastatic Spine Disease
por: Zhang, Hao-ran, et al.
Publicado: (2020)

Stereotactic body radiotherapy for metastatic sarcoma to the lung: adding to the arsenal of local therapy
por: Gutkin, Paulina M., et al.
Publicado: (2023)

Developments in Stereotactic Body Radiotherapy
por: Haridass, Anoop
Publicado: (2018)

A phase II trial of stereotactic body radiotherapy with concurrent anti-PD1 treatment in metastatic melanoma: evaluation of clinical and immunologic response
por: De Wolf, Katrien, et al.
Publicado: (2017)

Editorial: Stereotactic body radiotherapy for lung cancer
por: Liu, An, et al.
Publicado: (2023)

Case Report: Treatment of Hypertrophic Cardiomyopathy With Stereotactic Body Radiotherapy
por: Xiao, Longzihui, et al.
Publicado: (2022)

Neutrophil-lymphocyte ratio as a prognostic factor for stereotactic body radiotherapy treatment of metastatic liver tumors
por: Xie, Xuyun, et al.
Publicado: (2020)

Analysis of Biologically Equivalent Dose of Stereotactic Body Radiotherapy for Primary and Metastatic Lung Tumors
por: Park, Sungkwang, et al.
Publicado: (2014)

Stereotactic Body Radiotherapy for Metastatic Lung Cancer as Oligo-Recurrence: An Analysis of 42 Cases
por: Takahashi, Wataru, et al.
Publicado: (2012)

Stereotactic body radiotherapy for adenoid cystic carcinoma metastatic to the lung: a case report
por: Kobayashi, Daijiro, et al.
Publicado: (2021)

Abscopal effect in metastatic breast cancer treated with stereotactic body radiotherapy in the absence of immunotherapy
por: Kim, Jae Sik, et al.
Publicado: (2023)

Effects of two different radiotherapies for craniopharyngiomas using stereotactic radiosurgery/ stereotactic radiotherapy or fractionated stereotactic radiotherapy
por: Kamogawa, Misaki, et al.
Publicado: (2022)

Stereotactic Body Radiotherapy for Prostate Cancer
por: Parikh, Neil R., et al.
Publicado: (2020)

Stereotactic ablative body radiotherapy in patients with prostate cancer
por: Loblaw, Andrew, et al.
Publicado: (2018)

Stereotactic body radiotherapy for superior vena cava syndrome
por: Zhu, Xu, et al.
Publicado: (2022)

The impact of radiosensitivity on clinical outcomes of spinal metastases treated with stereotactic body radiotherapy
por: Guo, Lanlan, et al.
Publicado: (2023)

Local effect of stereotactic body radiotherapy for primary and metastatic liver tumors in 130 Japanese patients
por: Yamashita, Hideomi, et al.
Publicado: (2014)

Treatment of Residual, Recurrent, or Metastatic Intracranial Hemangiopericytomas With Stereotactic Radiotherapy Using CyberKnife
por: Huang, Lichao, et al.
Publicado: (2021)

Re-Irradiation With Stereotactic Body Radiotherapy for In-Field Recurrence of Pancreatic Cancer After Prior Stereotactic Body Radiotherapy: Analysis of 24 Consecutive Cases
por: Shen, Yuxin, et al.
Publicado: (2021)

Bibliometric Analysis of the Top-Cited Publications and Research Trends for Stereotactic Body Radiotherapy
por: Liu, Yanhao, et al.
Publicado: (2021)

Stereotactic body radiotherapy for solitary spine metastasis
por: Lee, Sunyoung, et al.
Publicado: (2013)

A Survey of Stereotactic Body Radiotherapy in Korea
por: Bae, Sun Hyun, et al.
Publicado: (2015)

Stereotactic body radiotherapy in lung cancer: an update
por: Abreu, Carlos Eduardo Cintra Vita, et al.
Publicado: (2015)

Stereotactic Body Radiotherapy for the Treatment of Renal Tumors()
por: Hanzly, Michael, et al.
Publicado: (2014)

Stereotactic Body Radiotherapy for Primary Prostate Cancer
por: Kothari, Gargi, et al.
Publicado: (2018)

Editorial: Stereotactic body radiotherapy for prostate cancer
por: Kishan, Amar U., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_osh10q13rtb3ncljaqmhslnnt7